文献速递脑血管病

阿哌沙班与阿司匹林在癌症合并隐源性卒中患者中的比较:ARCADIA随机临床试验的事后分析

Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke: A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2024-01-01

该研究为ARCADIA试验的事后分析,纳入1015例近期隐源性卒中且伴心房病变生物标志物的患者,其中137例(13.5%)有癌症史。在癌症史患者中,阿哌沙班组与阿司匹林组的主要缺血或出血事件风险无显著差异(HR 0.61;95%CI 0.26-1.43)。

要点

  • 有癌症史者较无癌症史者主要缺血或出血事件风险更高(HR 1.73;95%CI 1.10-2.71)。
  • 癌症史患者中阿哌沙班组与阿司匹林组主要事件风险无显著差异(HR 0.61;95%CI 0.26-1.43)。
  • 癌症史患者中阿哌沙班组与阿司匹林组的事件率分别为13.1%与21.1%。

核心结论

  • 在ARCADIA试验有癌症史的患者中,阿哌沙班与阿司匹林相比,主要缺血和出血事件风险无显著差异。

研究设计与样本

  • ARCADIA试验的事后分析,该试验为多中心、随机、双盲临床试验,2018年至2023年在北美185个卒中中心进行,共纳入1015例近期隐源性卒中且伴心房病变生物标志物的患者。
  • 数据分析时间为2023年10月15日至2024年5月23日。
  • 暴露为口服阿哌沙班5 mg(符合标准时2.5 mg)每日两次 vs 口服阿司匹林81 mg每日一次。
  • 按基线有无癌症史检查亚组。

主要发现

  • 1015例参与者中位(IQR)年龄68(60-76)岁,551例(54.3%)为女性,137例(13.5%)有癌症史。
  • 有癌症史者中位(IQR)随访1.5(0.6-2.5)年,无癌症史者为1.5(0.6-3.0)年。
  • 有癌症史者较无癌症史者主要缺血或主要出血事件风险更高(HR 1.73;95%CI 1.10-2.71)。
  • 有癌症史者中,随机分配至阿哌沙班组61例中8例(13.1%)和随机分配至阿司匹林组76例中16例(21.1%)发生主要缺血或主要出血事件,但组间风险无显著差异(HR 0.61;95%CI 0.26-1.43)。
  • 有癌症史者中,阿哌沙班组 vs 阿司匹林组的事件包括复发性卒中(5例[8.2%] vs 9例[11.8%])、主要缺血事件(7例[11.5%] vs 14例[18.4%])和主要出血事件(1例[1.6%] vs 2例[2.6%])。

关键数值与推荐

  • 主要结局为重大缺血或重大出血事件的复合终点。
  • 重大缺血事件包括复发性缺血性卒中、心肌梗死、系统性栓塞以及症状性深静脉血栓或肺栓塞。
  • 重大出血事件包括症状性颅内出血和任何重大颅外出血。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Approximately 10% to 15% of ischemic strokes are associated with cancer; cancer-associated stroke, particularly when cryptogenic, is associated with high rates of recurrent stroke and major bleeding. Limited data exist on the safety and efficacy of different antithrombotic strategies in patients with cancer and cryptogenic stroke. OBJECTIVE: To compare apixaban vs aspirin for the prevention of adverse clinical outcomes in patients with history of cancer and cryptogenic stroke. DESIGN, SETTING, AND PARTICIPANTS: Post hoc analysis of data from 1015 patients with a recent cryptogenic stroke and biomarker evidence of atrial cardiopathy in the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial, a multicenter, randomized, double-blind clinical trial conducted from 2018 to 2023 at 185 stroke centers in North America. Data analysis was performed from October 15, 2023, to May 23, 2024. EXPOSURES: Oral apixaban, 5 mg (or 2.5 mg if criteria met), twice daily vs oral aspirin, 81 mg, once daily. Subgroups of patients with and without cancer at baseline were examined. MAIN OUTCOMES AND MEASURES: The primary outcome for this post hoc analysis was a composite of major ischemic or major hemorrhagic events. Major ischemic events were recurrent ischemic stroke, myocardial infarction, systemic embolism, and symptomatic deep vein thrombosis or pulmonary embolism. Major hemorrhagic events included symptomatic intracranial hemorrhage and any major extracranial hemorrhage. RESULTS: Among 1015 participants (median [IQR] age, 68 [60-76] years; 551 [54.3%] female), 137 (13.5%) had a history of cancer. The median (IQR) follow-up was 1.5 (0.6-2.5) years for patients with history of cancer and 1.5 (0.6-3.0) years for those without history of cancer. Participants with history of cancer, compared with those without history of cancer, had a higher risk of major ischemic or major hemorrhagic events (hazard ratio [HR], 1.73; 95% CI, 1.10-2.71). Among those with history of cancer, 8 of 61 participants (13.1%) randomized to apixaban and 16 of 76 participants (21.1%) randomized to aspirin had a major ischemic or major hemorrhagic event; however, the risk was not significantly different between groups (HR, 0.61; 95% CI, 0.26-1.43). Comparing participants randomized to apixaban vs aspirin among those with cancer, events included recurrent stroke (5 [8.2%] vs 9 [11.8%]), major ischemic events (7 [11.5%] vs 14 [18.4%]), and major hemorrhagic events (1 [1.6%] vs 2 [2.6%]). CONCLUSIONS AND RELEVANCE: Among participants in the ARCADIA trial with history of cancer, the risk of major ischemic and hemorrhagic events did not differ significantly with apixaban compared with aspirin. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03192215.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Navi BB, Zhang C, Miller B, et al. Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke: A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial. JAMA Neurol. 2024. PMID: 39133474. doi:10.1001/jamaneurol.2024.2404

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。